Iptacopan · Fabhalta
Small molecule
Also known as LNP023
Evidence outlook
Approved: Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy, Complement-Mediated Renal Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Chronic Kidney Disease · Phase 3Age-Related Macular Degeneration · Phase 2Generalized Myasthenia Gravis · Phase 3
Also approved (5)
- Complement 3 Glomerulopathy FABHALTA is indicated for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.
- Adult patients with complement 3 glomerulopathy (C3G)
- Monotherapy in adult patients with paroxysmal nocturnal haemoglobinuria (PNH)
- Paroxysmal nocturnal haemoglobinuria (PNH), adults; Japanese brand name written Fabihalta in katakana; date from the Novartis Japan release of 2024-06-24
- Adult PNH patients who have not previously received complement inhibitor therapy (NMPA notice updated 2024-04-30)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04558918 NCT04558918 · Paroxysmal Nocturnal Hemoglobinuria This randomized trial compared iptacopan with continued standard anti-C5 antibody therapy and met both main measures by a wide margin, and those measures are based on hemoglobin, a laboratory value. Patients and doctors knew which treatment was given and the trial was modest in size (97 patients), so the design falls short of the highest grade. Registry: NCT04558918 | 3 | Marginal Proportion (Expressed as Percentages) of Participants With Sustained Increase in Hemoglobin Levels From Baseline of ≥ 2 g/dL in the Absence of Red Blood Cell Transfusions; Marginal Proportion (Expressed as Percentages) of Participants With Sustained Hemoglobin Levels of ≥ 12 g/dL in the Absence of Red Blood Cell Transfusions 2022-09-26 | At 24 weeks, without transfusion: Hb increase of 2 g/dL or more in 51 of 60 on iptacopan vs 0 of 35 on anti-C5; Hb of 12 g/dL or more in 42 of 60 vs 0 of 35. Superiority shown on both primaries. | Partial signal | link ↗ |
View 1 more trial
APPOINT-PNH NCT04820530 · Paroxysmal Nocturnal Hemoglobinuria The study was an open-label, single-arm trial of 40 participants receiving iptacopan, without randomization or a placebo/active comparator. Although the clinical primary endpoint was reported as 92.2% responders, the uncontrolled design cannot establish how much of the result was due to iptacopan. Registry: NCT04820530 | 3 | Marginal Proportion (Expressed as Percentage) of Participants With Sustained Increase in Hemoglobin Levels From Baseline of ≥ 2 g/dL in the Absence of Red Blood Cell Transfusions 2022-11-02 | Single arm, 24 weeks: estimated 92.2% (95% CI 82.5 to 100.0) of 40 complement-inhibitor-naive patients had a sustained Hb increase of 2 g/dL or more without transfusion. No comparator. | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (15)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Early phase / not applicable (2)
What this study did
What this study did
Competitive landscape
Other Complement Factor B drugs
HRS-5965, FWY003, ALN-CFB. Compare all 4 Complement Factor B drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Paroxysmal Nocturnal Hemoglobinuria: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Iptacopan (Fabhalta): this drug | Approved | Small molecule | Complement Factor B | Partial signal | NCT04558918: At 24 weeks, without transfusion: Hb increase of 2 g/dL or more in 51 of 60 on iptacopan vs 0 of 35 on anti-C5; Hb of 12 g/dL or more in 42 of 60 vs 0 of 35. Superiority shown on both primaries. NCT04820530: Single arm, 24 weeks: estimated 92.2% (95% CI 82.5 to 100.0) of 40 complement-inhibitor-naive patients had a sustained Hb increase of 2 g/dL or more without transfusion. No comparator. | |
| Eculizumab (Soliris) | Approved | Monoclonal antibody | Complement C5 | Weak signal | Featured results are safety only in this race | |
| Pegcetacoplan (Empaveli) | Approved | Peptide | Complement C3 | Partial signal | NCT03500549: Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP (Baseline and Week 16): Pegcetacoplan to Pegcetacoplan 2.37 Grams per deciliter (g/dL) (Standard Error 0.363) | Eculizumab to Pegcetacoplan -1.47 Grams per deciliter (g/dL) (Standard Error 0.666) | |
| Ravulizumab (Ultomiris) | Approved | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-5965 | Phase 3 | Undisclosed | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication | |
| Pozelimab (Veopoz) | Phase 3 | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| FWY003 | Phase 2(overall) | Undisclosed | Complement Factor B | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Zaltenibart | Phase 2 | Monoclonal antibody | MASP-3 | Weak signal | NCT05972967: Interim (data cut-off 8 July 2024): primary endpoints were safety and tolerability; zaltenibart was well tolerated, treatment-related adverse events in 46.2% of patients (mostly mild to moderate), 1 discontinuation for a treatment-emergent serious adverse event. Hemoglobin rose from a mean baseline of 9.26 g/dL by 3.39 g/dL at day 29 and 3.27 g/dL at day 169 on add-on to ravulizumab (N=13), and by 3.85 g/dL at day 309 on monotherapy (N=6, P=0.003). | |
| ALN-CFB | Phase 1/2 | RNA / oligonucleotide | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(13 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Fabhalta (Iptacopan) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (5)
January 2027 (1)
April 2027 (1)
What to watch
October 2027 (1)
What to watch
November 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (2)
2030 (2)
2031 (1)
October 2031 (1)
What to watch
2032 (1)
July 2032 (1)
What to watch
2036 (1)
May 2036 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent